Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foretinib plus Lapatinib in HER2+ Metastatic Breast Cancer
NCT01138384Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Oct 2010
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of foretinib in HER2-positive breast cancer, sponsored by Canadian Cancer Trials Group. Started Oct 2010; status: completed.
02
Drugs
foretinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01138384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01138384.